HLB Pharmaceutical (Korea) Performance
| 047920 Stock | KRW 23,400 700.00 2.90% |
The company owns a Beta (Systematic Risk) of -0.57, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning HLB Pharmaceutical are expected to decrease at a much lower rate. During the bear market, HLB Pharmaceutical is likely to outperform the market. At this point, HLB Pharmaceutical has a negative expected return of -0.0444%. Please make sure to check out HLB Pharmaceutical's coefficient of variation, jensen alpha, and the relationship between the mean deviation and standard deviation , to decide if HLB Pharmaceutical performance from the past will be repeated in the future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days HLB Pharmaceutical Co has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, HLB Pharmaceutical is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Total Cashflows From Investing Activities | -15.8 B |
HLB |
HLB Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 2,565,000 in HLB Pharmaceutical Co on August 28, 2024 and sell it today you would lose (225,000) from holding HLB Pharmaceutical Co or give up 8.77% of portfolio value over 90 days. HLB Pharmaceutical Co is generating negative expected returns and assumes 5.0102% volatility on return distribution over the 90 days horizon. Simply put, 44% of stocks are less volatile than HLB, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
HLB Pharmaceutical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for HLB Pharmaceutical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as HLB Pharmaceutical Co, and traders can use it to determine the average amount a HLB Pharmaceutical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0089
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 047920 |
Estimated Market Risk
| 5.01 actual daily | 44 56% of assets are more volatile |
Expected Return
| -0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average HLB Pharmaceutical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of HLB Pharmaceutical by adding HLB Pharmaceutical to a well-diversified portfolio.
HLB Pharmaceutical Fundamentals Growth
HLB Stock prices reflect investors' perceptions of the future prospects and financial health of HLB Pharmaceutical, and HLB Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on HLB Stock performance.
| Return On Equity | -11.39 | |||
| Return On Asset | 0.0219 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 216.14 B | |||
| Shares Outstanding | 13.85 M | |||
| Price To Sales | 5.60 X | |||
| Revenue | 62.85 B | |||
| EBITDA | 3.08 B | |||
| Cash And Equivalents | 6.64 B | |||
| Total Debt | 2.14 B | |||
| Debt To Equity | 0.74 % | |||
| Cash Flow From Operations | (1.32 B) | |||
| Total Asset | 127.63 B | |||
About HLB Pharmaceutical Performance
By analyzing HLB Pharmaceutical's fundamental ratios, stakeholders can gain valuable insights into HLB Pharmaceutical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if HLB Pharmaceutical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if HLB Pharmaceutical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
HLB Pharmaceutical Co., Ltd, a pharmaceutical company, develops peptide drugs in South Korea. HLB Pharmaceutical Co., Ltd was founded in 1998 and is headquartered in Namyangju, South Korea. HLBPHARMA is traded on Korean Securities Dealers Automated Quotations in South Korea.Things to note about HLB Pharmaceutical performance evaluation
Checking the ongoing alerts about HLB Pharmaceutical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for HLB Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| HLB Pharmaceutical generated a negative expected return over the last 90 days | |
| HLB Pharmaceutical has high historical volatility and very poor performance | |
| The company reported the revenue of 62.85 B. Net Loss for the year was (13.23 B) with profit before overhead, payroll, taxes, and interest of 18.04 B. | |
| HLB Pharmaceutical Co has accumulated about 6.64 B in cash with (1.32 B) of positive cash flow from operations. | |
| Roughly 26.0% of the company shares are owned by insiders or employees |
- Analyzing HLB Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether HLB Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining HLB Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating HLB Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of HLB Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of HLB Pharmaceutical's stock. These opinions can provide insight into HLB Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for HLB Stock analysis
When running HLB Pharmaceutical's price analysis, check to measure HLB Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HLB Pharmaceutical is operating at the current time. Most of HLB Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of HLB Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HLB Pharmaceutical's price. Additionally, you may evaluate how the addition of HLB Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |